Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double Blind, Placebo-Controlled, Multicenter Study to Evaluate Safety, Dosing Schedule and Antibody Kinetics of Recombinant Botulinum Vaccine A/B, rBV A/B-40, in Healthy Adults

NCT00764634 is registered in ClinicalTrials.gov with DynPort Vaccine Company LLC, A GDIT Company as lead sponsor.

NCT NCT00764634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00764634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double Blind, Placebo-Controlled, Multicenter Study to Evaluate Safety, Dosing Schedule and Antibody Kinetics of Recombinant Botulinum Vaccine A/B, rBV A/B-40, in Healthy Adults
Lead sponsor
DynPort Vaccine Company LLC, A GDIT Company
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2008
Completion date
December 31, 2010
Enrollment
440 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

botulism vaccine